Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 3:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 3,389 matching trials from the live ClinicalTrials.gov search.
Conditions
Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
imatinib mesylate, bevacizumab, pharmacological study, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer
Interventions
XMT-2056
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Stanford, California • Celebration, Florida + 8 more
Conditions
Advanced Cancer, Advanced Solid Tumors
Interventions
ALK201
Drug
Lead sponsor
Shanghai Allink Biotherapeutics Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Denver, Colorado • Orlando, Florida • New Orleans, Louisiana + 1 more
Conditions
Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more
Conditions
Adult Solid Neoplasm
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Solid Tumors
Interventions
BMS-986156, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • La Jolla, California • Atlanta, Georgia + 4 more
Conditions
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Conditions
Advanced Solid Tumors, Tumors, Cancer
Interventions
MK-2206, Paclitaxel, Trastuzumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Francisco, California
Conditions
Solid Tumors
Interventions
bevacizumab, everolimus, panitumumab
Drug
Lead sponsor
Herbert Hurwitz, MD
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Solid Tumors
Interventions
ETC-1922159, Pembrolizumab
Drug
Lead sponsor
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Government
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
9
States / cities
Tucson, Arizona • Orange, California • Aurora, Colorado + 5 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
capecitabine, imatinib mesylate
Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
oxaliplatin, fluorouracil, leucovorin calcium, pharmacological study, positron emission tomography, computed tomography
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Solid Tumors
Interventions
ZW191
Drug
Lead sponsor
Zymeworks BC Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
New Haven, Connecticut • Columbus, Ohio • Oklahoma City, Oklahoma + 2 more
Conditions
Adult Solid Neoplasm
Interventions
Erlotinib Hydrochloride, Irinotecan Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Any Advanced Solid Tumors
Interventions
Sarilumab, ICI Therapy
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Interventions
PI-88
Drug
Lead sponsor
Cellxpert Biotechnology Corp.
Industry
Eligibility
18 Years to 120 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Dual-Energy Computed Tomography
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Solid Tumor, Locally Advanced Solid Tumor
Interventions
Topical Tretinoin, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Endometrial Cancer, Malignant Solid Tumour
Interventions
Puxitatug Samrotecan, Doxorubicin, Paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
69
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 60 more
Conditions
Small Cell Lung Cancer
Interventions
IMGN901, Carboplatin and Etoposide
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
32
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 23 more
Conditions
Solid Tumor, Adult
Interventions
FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more
Conditions
Solid Tumors
Interventions
Ramucirumab (IMC-1121B), Irinotecan, Folinic acid, 5-Fluorouracil
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Detroit, Michigan • Las Vegas, Nevada • Cleveland, Ohio + 2 more
Conditions
Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
Interventions
TT-10, TT-4
Drug
Lead sponsor
Portage Biotech
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Conditions
Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
Interventions
PRT3789, pembrolizumab
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
West Palm Beach, Florida • Detroit, Michigan • Hackensack, New Jersey + 2 more